Last Chance | Book your ticket now - Life Sciences Investor Briefing with speakers from Destiny Pharma (DEST), Open Orphan (ORPH), Shield Therapeutics (STX) and Hardman & Co.

London South East Investor Briefing 2019 No Images? [Click here]( [London South East]( [LAST CHANCE - Book your FREE ticket now]( Natural Resources Investor Briefing Join us at Brewers Hall for the next Investor Briefing in our 2019 season, brought to you in partnership with Hardman & Co and in association with our sponsors City Index. Our focus this time around is life Sciences, and we would like to introduce you to some great investment opportunities. Date / Time: Wednesday 11th September 2019 Cost: FREE Location: Brewers' Hall, Aldermanbury Square, London, EC2V 7HR Speaker Line Up Neil Clark, CEO, Destiny Pharma Destiny Pharma plans to generate income and shareholder value by the clinical development and commercial exploitation of its proprietary, highly innovative anti-bacterial drug platform. The XF drug platform is being developed to prevent and treat existing and emerging superbug infections within and outside of hospitals. The main market for the lead asset XF-73, which is currently in Phase 2 clinical studies, is the prevention of post-surgical infections such as MRSA. The commercial focus is initially in the USA but the need for a new treatment is global and Destiny Pharma has the ability to enter into licensing agreements and collaborations for other territories in due course. For example, the agreement signed in 2017 with China Medical Systems is a broad collaboration to develop the company’s assets in the China/Asia market. The Board believes that the increasing governmental pressure and financial incentives that are being implemented now and possibly in the future by leading institutions such as the WHO, UN, FDA and G7/G20 will increase further the options available for profitable commercialisation and the generation of shareholder value. (Ticker: DEST / Index: AIM / Sector: Pharmaceuticals) [View More Details]( Tim Watts, Chief Financial Officer, Shield Therapeutics Shield is a de-risked, commercial stage, speciality pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Group has a marketed product, Feraccru®/Accrufer®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru®/Accrufer® is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the European Union by Norgine BV, with a US commercialisation partner currently being selected. (Ticker: STX / Index: AIM / Sector: Pharmaceuticals) [View More Details]( Cathal Friel, CEO, Open Orphan Open Orphan completed its IPO on the 28 June 2019 with a reverse takeover of Venn Life Sciences. The new management team has a track record of building successful businesses and we plan to expand by acquiring a number of small European pharma services companies whilst developing one of Europe’s largest rare disease genomic databanks, the Open Orphan Health Data platform. Furthermore, Open Orphan is bringing its digital Virtual Rep platform services to pharma companies, allowing large pharma companies to benefit from the digital world. Open Orphan CEO Cathal Friel was also the co-founder and remains one of the largest shareholders in Amryt Pharma plc which is currently in the process of moving from a £50m to c. $300m market cap having acquired North American company Aegerion Pharmaceuticals Inc. (Ticker: ORPH / Index AIM & Euronext Growth / Sector: Services) [View More Details]( Dr Martin Hall is the Head of Life Sciences at Hardman & Co. For over 20 years, Hardman & Co has built a reputation for research of the highest quality, provided by a team of highly skilled and qualified industry professionals. The Life Sciences team, led by Dr Martin Hall, has a reputation for opinionated research that is distributed globally in the fields of pharmaceuticals, biotechnology, medical technology and healthcare. Our strengths are industry knowledge, quality of product, and excellent distribution. Our reports tend to be more in-depth and more educational, but still getting messages across to all pools of capital, so they sit comfortably alongside, and are complementary to those of the company’s own broker. Nigel Cassidy, Host Nigel Cassidy, our regular event presenter, is a highly experienced financial host, writer and broadcaster – perhaps best known for his years presenting the business news on BBC Radio 4’s iconic Today programme, and for the time he spent on the road as a roving TV business correspondent for BBC World News. He also hosted Share Radio’s breakfast show. [Book your free ticket today]( This event is suitable for sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists. Be aware the price of stocks can go up and down and your capital is at risk. London South East Ltd 7th Floor, Maitland House, Southend-on-Sea, SS1 2JY info@lse.co.uk | +44 (0)203 011 0760 Share Prices, Stock Quotes, Charts, Trade History, Share Chat, & Financial News [Like]( [Tweet]( [Share]( [Forward]( [Preferences]( | [Unsubscribe](